High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method

Reference

• ANZENBACHEROVA, E., ANZENBACHER, P., PERLIK, F. and KVETINA, J., 2000, Use of a propafenone metabolic ratio as a measure of CYP2D6 activity. International Journal of Clinical Pharmacology and Therapeutics, 38, 426–429.
   PubMed Web of Science ®Google Scholar
• BAPIRO, T. E., EGNELL, A. C., HASLER, J. A. and MASIMIREMBWA, C. M., 2001, Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metabolism and Disposition, 29, 30–35.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analytical Biochemistry, 248, 188–190.
   PubMed Web of Science ®Google Scholar
• FAVREAU, L. V., PALAMANDA, J. R., LIN, C. C. and NOMEIR, A. A., 1999, Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metabolism and Disposition, 27, 436–439.
   PubMed Web of Science ®Google Scholar
• GAO, F., JOHNSON, D. L., EKINS, S., JANISZEWSKI, J., KELLY, K. G., MEYER, R. D. and WEST, M., 2002, Optimizing higher throughput methods to assess drug—drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC50. Journal of Biomolecular Screening, 7, 373–382.
   PubMed Web of Science ®Google Scholar
• GREENBLATT, D. J., Von MOLTKE, L. L., HARMATZ, J. S., COUNIHAN, M., GRAF, J. A., DUROL, A. L., MERTZANIS, P., DUAN, S. X., WRIGHT, C. E. and SHADER, R. I., 1998, Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clinical Pharmacology and Therapeutics, 64, 278–285.
   PubMed Web of Science ®Google Scholar
• KANAMITSU, S., ITO, K., GREEN, C. E., TYSON, C. A., SHIMADA, N. and SUGIYAMA, Y., 2000, Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharmaceutical Research, 17, 419–426.
   PubMed Web of Science ®Google Scholar
• MA, B., PRUEKSARITANONT, T. and LIN, J. H., 2000, Drug interactions with calcium channel blockers: possible involvement of metabolite—intermediate complexation with CYP3A. Drug Metabolism and Disposition, 28, 125–130.
   PubMed Web of Science ®Google Scholar
• MCGINNITY, D. F. and RILEY, R. J., 2001, Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochemical Society Transactions, 29, 135–139.
   PubMed Web of Science ®Google Scholar
• MILLER, V. P., STRESSER, D. M., BLANCHARD, A. P., TURNER, S. and CRESPI, C. L., 2000, Fluorometric high-throughput screening for inhibitions of cytochrome P450. Annals of the New York Academy of Sciences, 919, 26–32.
   PubMedGoogle Scholar
• MOODY, G. C., GRIFFIN, S. J., MATHER, A. N., MCGINNITY, D. F. and RILEY, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53–75.
   PubMed Web of Science ®Google Scholar
• NOMEIR, A. A., RUEGG, C., SHOEMEKER, M., FAVREAU, L. V., PALAMANDA, J. R., SILBER, P. and LIN, C. C., 2001, Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metabolism and Disposition, 29, 748–753.
   PubMed Web of Science ®Google Scholar
• OHYAMA, K., NAKAJIMA, M., SUZUKI, M., SHIMADA, N., YAMAZAKI, H. and YOKOI, T., 2000, Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. British Journal of Clinical Pharmacology, 49, 244–253.
   PubMed Web of Science ®Google Scholar
• PALAMANDA, J. R., FAVREAU, L., CHUNG, C. and NOMEIR, A. A., 1998, Validation of a rapid microtiter plate assay to conduct cytochrome P450 2D6 enzyme inhibition studies. Drug Discovery Today, 3, 466–470.
   Google Scholar
• STRESSER, D. M., BLANCHARD, A. P., TURNER, S. D., ERVE, J. C., DANDENEAU, A. A., MILLER, V. P. and CRESPI, C. L., 2000, Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metabolism and Disposition, 28, 1440–1448.
   PubMed Web of Science ®Google Scholar
• SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO, T., Suzum, A. and KOHNO, Y., 2002, Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibitory patterns. Drug Metabolism and Pharmacokinetics, 17, 437–448.
   PubMedGoogle Scholar
• YAMAMOTO, T., Suzum, A. and KOHNO, Y., 2003, High throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtiter plate assay using a combination of recombinant CYP2D6. Xenobiotica, 33, 823–839.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., URANO, T., HIROKI, S. and SHIMADA, T., 1996, Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. Journal of Toxicological Sciences, 21, 215–226.
   PubMedGoogle Scholar
• YEO, K. R. and YEO, W. W., 2001, Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. British Journal of Clinical Pharmacology, 51, 461–470.
   PubMed Web of Science ®Google Scholar
• ZHOU, S., CHIANG, D., CHIN, R., KESTELL, P. and PAXTON, J. W., 2002, High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Journal of Chromatography B, Biomedical Applications, 767, 19–26.
   Google Scholar